It is made available under a CC-BY-ND 4.0 International license.

Article 1

Effect of a novel food rich in miraculin on the intestinal micro- ² **biome of malnourished patients with cancer and dysgeusia** ³

Julio Plaza-Diaz1,2,3, Marco Brandimonte-Hernández1, Bricia López-Plaza4,5, Francisco Javier Ruiz-Ojeda1,6,7,8, Ana 4 **Isabel Álvarez-Mercado2,6,9, Lucía Arcos-Castellanos4, Jaime Feliú-Batlle10,11,12, Thomas Hummel13, Samara Palma** 5 **Milla4,12,14,†, Angel Gil1,2,6,7,†,*** 6

- ¹ Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 7 Granada, Spain. 8
- ² Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, 9 18014 Granada, Spain. 10
- ³ Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada. 11
- ⁴ Food, Nutrition and Health Platform, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, 12 Spain. 13
- ⁵ Medicine Department, Faculty of Medicine, Complutense University of Madrid, Plaza de Ramón y Cajal, 14 s/n, 28040 Madrid, Spain. 15
- ⁶ Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research, University of 16 Granada, Avda. del Conocimiento s/n. Armilla, 18016 Granada, Spain. 17
- ⁷ CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, 18 Spain. 19
- ⁸ RU Adipocytes and Metabolism, Helmholtz Diabetes Center at Helmholtz Munich, German Research Cen- 20 ter for Environmental Health GmbH Neuherberg, 85764, Germany. 21
- ⁹ Department of Pharmacology, University of Granada, 18071 Granada, Spain. 22
- ¹⁰ Oncology Department, Hospital La Paz Institute for Health Research-IdiPAZ, Hospital Universitario La 23 Paz, 28029 Madrid, Spain. 24
- ¹¹ CIBERONC (CIBER Cancer), Instituto de Salud Carlos III, 28029 Madrid, Spain. 25
- ¹² Medicine Department, Faculty of Medicine, Autonomous University of Madrid, Arzobispo Morcillo 4, 26 28029 Madrid, Spain. 27
- ¹³ Smell & Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Fetscherstraße 28 74, 01307 Dresden, Germany. 29
- ¹⁴ Nutrition Department, Hospital University La Paz, 28046 Madrid, Spain. 30
- † These authors contributed equally to this work 31
- ***** Correspondence: agil@ugr.es (A.G.); Tel.: +34-695466922 (A.G.) 32

Abstract: Dysgeusia contributes to nutritional derangement and worsens the quality of life of pa- 33 tients with cancer. Despite the different strategies, there is no effective treatment for patients suffer- 34 ing from taste disorders provided by the pharmaceutical industry. We developed a novel strategy 35 for reducing side effects in cancer patients by providing a novel food supplement with the taste- 36 modifying glycoprotein miraculin, which is approved by the European Union, as an adjuvant to 37 medical-nutritional therapy. A pilot randomized, parallel, triple-blind, and placebo-controlled in- 38 tervention clinical trial was carried out in which 31 malnourished patients with cancer and dysgeu- 39 sia receiving antineoplastic treatment, and were randomized into three arms: standard dose of DMB 40 (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried straw- 41 berry) for three months. Patients consumed a DMB or placebo tablet before each main meal (break- 42 fast, lunch and dinner). Using stool samples from patients with cancer, we analyzed the intestinal 43 microbiome via nanopore methodology. We detected differences in the relative abundances of gen- 44 era *Phocaeicola* and *Escherichia* depending on the treatment. Nevertheless, only the *Solibaculum* genus 45 was more abundant in the standard-dose DMB group after 3 months. At the species level, *Bacteroides* 46 sp. PHL 2737 presented a relatively low abundance in both DMB groups, and *Vescimonas coprocola* 47 presented a relatively high abundance in both treatment groups after 3 months. Furthermore, a 48 standard dose of DMB was positively associated with TNF-α levels and *Lachnoclostridium* and *Med-* 49 *iterraneibacter* abundances, whereas a high dose of DMB was negatively associated with TNF-α lev- 50 els and the relative abundance of *Phocaeicola*. After a high dose of DMB, erythrocyte polyunsaturated 51
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide s new research that has not been certified by peer review and should not be used to guide clinical practice.
fatty acids were positively correlated with *Lachnoclostridium* and *Roseburia*, and there was a positive 52

association between *Phocaeicola* and the acetic acid concentration of feces. The intake of DMB 53

It is made available under a CC-BY-ND 4.0 International license.

together with nutritional treatment and individualized dietary advice results in positive changes in 54 the intestinal microbiome of patients with cancer and dysgeusia There was a negative association 55 between the relative abundance of *Phocaeicola* and taste perception in the DMB high dose group. 56 Changes observed in the intestinal microbiota might contribute to maintaining an appropriate im- 57 mune response of cancer patients. Since the present pilot study involved only a few participants, 58 further research is needed to draw robust conclusions. 59

Keywords: cancer, neoplasms, dysgeusia, malnutrition, intestinal microbiota, dried miracle berries, 60 taste disorders. $\qquad \qquad 61$

62

1. Introduction 63

Cancer is characterized by uncontrolled cell proliferation [1]. The disease affects peo- 64 ple in many ways, including psychologically, physically, economically, and socially [2]. 65 Many patients with cancer may benefit from systemic therapy, chemotherapy, and radio- 66 therapy; however, these treatments are also associated with a high risk of serious compli- 67 cations [3]. 68

Malnutrition is estimated to be responsible for the death of 10-20% of patients with 69 cancer [4]. However, nutritional support is received by only 30%-60% of cancer patients 70 who are at risk of malnutrition [4]. 71

Despite possible adverse consequences, taste changes experienced by patients with 72 cancer are not usually diagnosed and treated early because clinicians do not consider them 73 life-threatening [5-7]. It is estimated that 45 to 80% of patients with chemotherapy-induced 74 taste changes will experience these changes [8-10]. Dysgeusia is the umbrella term for 75 qualitative and quantitative taste dysfunction, and includes taste distortions with bitter, 76 metallic, salty, or unpleasant tastes [11-13]. The consequences of taste alterations are the 77 deterioration of nutritional status, a reduction in quality of life, weight loss, and ulti- 78 mately, health [14-17]. Zinc, amifostine, selenium, lactoferrin, and cannabinoids are cur- 79 rently used to treat taste disorders; however, their effectiveness is limited [18-20]. 80

The gut microbiota plays a crucial role in maintaining health, influencing not only 81 the gastrointestinal tract, but also distant organs such as the brain, liver, and pancreas 82 [21,22]. The composition of the gut microbiota is diverse: it is composed of more than 200 83 bacterial species [23,24] (including phylotypes such as *Bacillota, Bacteroidota, Actinomyces,* 84 *Fusobacterium, Pseudomonadota, and Verrucomicrobiota*) [25], fungi (*Candida albicans*), viruses 85 and protists [26]. Microorganisms that belong to a separate kingdom of living organisms, 86 *Archaebacteria*, are also an important part of the intestinal microbiota [27]. An alteration in 87 the equilibrium of the gut microbiota can result in the development of a dysbiotic state, 88 with subsequent implications for both local and systemic health outcomes [28]. Thus, 89 dysbiosis contributes to a variety of pathologies, including obesity [29], diabetes [30], neu- 90 rodegenerative diseases [31], and cancer [32]. Approximately 20% of all cancers are 91 strongly associated with specific viral or microbial infections [33]. Furthermore, bacteria 92 have been identified as key factors in the progression of several types of cancer, including 93 oral squamous cell carcinomas, colorectal cancer, and pancreatic ductal adenocarcinoma 94 [34-36]. 95

The complexity of the gut microbiome, as well as its richness and abundance, predicts 96 the metabolic health of the host [37]. Several factors contribute to the composition of the 97 gut microbiome, including diet and dietary habits. Unsurprisingly, the gut microbiome 98 has been associated with several cancer determinants, such as taste perception, which in- 99 fluences appetite regulation and energy metabolism [37]. Furthermore, there is evidence 100 that the gut microbiota can affect the response to systemic cancer therapy [38]. 101

Miraculin is a glycoprotein obtained from the *Synsepalum dulcificum* berries that con- 102 verts a sour taste into a sweet taste, which is why the fruit is also called "miracle berry" 103 [39]. The taste-modifying effect of miraculin occurs under acidic conditions and lasts for 104 approximately 30 minutes after consumption. Two small non-randomized studies using 105

It is made available under a CC-BY-ND 4.0 International license.

non-objective tools tried to evaluate the effect of miracle fruit on taste disorders in patients 106 with cancer who are receiving active chemotherapy treatment describing promising re- 107 sults [15,40]. Dried miracle berries (DMB) was approved as a novel food by the European 108 Commission in December 2021. In addition to its taste-modifying properties, DMB also 109 contains bioactive ingredients, such as fiber and phenolic compounds [41,42]. 110

In a pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial (the 111 CLINMIR study), our research group provided clinical evidence on the efficacy of DMB 112 in improving taste alterations in cancer patients. As a result of this study, we observed 113 improvements in electrochemical food perception, energy and nutrient intake, nutritional 114 status, and quality of life for malnourished patients with cancer receiving antineoplastic 115 treatment [43]. Moreover, we showed that regular consumption of DMB consumption and 116 nutritional interventions changed the oral microbiome in patients with cancer and dys- 117 geusia, which may contribute to maintaining an appropriate immune response without 118 altering taste perception [44]. The purpose of the present study was to assess the intestinal 119 microbiome of malnourished patients with cancer and dysgeusia after DMB consumption 120 as a medical-nutritional adjuvant treatment. 121

2. Results 122

During the period of November 2022 to May 2023, 62 patients were assessed for eli- 123 gibility. Among 31 patients with cancer who met the inclusion criteria, three intervention 124 groups were randomly assigned according to the type of cancer. In the course of the study, 125 ten participants withdrew from the study. Several of these dropouts were caused by taste 126 distortions caused by acidic foods that were not sweet ($n = 6$) and the complexity of the 127 intervention prescription ($n = 2$). During the course of the study, two placebo patients 128 died. A total of 21 patients with cancer completed the clinical trial. All variables were an- 129 alyzed with an intention-to-treat approach. The sample consisted of 58.1% women and 130 41.9% men, with an average age of 60.0 ± 10.9 years. Participants who were actively treated 131 were assessed by electrogustometry; results of taste perception for the population have 132 been published elsewhere [45]. 133

2.1. Phylum level 135

At baseline, *Bacillota* and *Bacteroidota* accounted for more than 80% of the relative 136 abundance of the intestinal microbiota. Based on the comparison between baseline and 137 three months, no major differences were found among the groups. According to the treat- 138 ment, only *Pseudomonadota* was significantly different among the three study groups. Both 139 the alpha diversity indices (Shannon, Simpson and Chao1) and the studied phyla did not 140 show any effect of treatment x time (Table 1). 141

2.2. Genus level 143

The most common genus in all the studied groups was *Faecalibacterium* (approxi- 144 mately 11 to almost 20 % relative abundance). There were differences between the genera 145 *Phocaeicola* and *Escherichia* depending on the treatment. For *Solibaculum*, we observed sig- 146 nificant differences in the interaction effect of treatment x time. The standard dose of DMB 147 produced a significant increase in the relative abundance of *Solibaculum*, whereas the pla- 148 cebo resulted in a significant decrease in the relative abundance of this genus (Table 2). 149

2.3. Species level 151

Four species dominated the intestinal microbiota of cancer patients: *Faecalibacterium* 152 *prausnitzii*, *Anaerobutyricum hallii*, and *Vescimonas coprocola* and *Vescimonas fastidiosa*. For 153 *Bacteroides* sp. PHL 2737 and *Vescimonas coprocola*, we observed significant differences in 154 the interaction between treatment and time; between baseline and 3 months, *Bacteroides* 155 sp. PHL 2737 decreased significantly in both the DMB groups and *Vescimonas coprocola* 156 decreased in the placebo group (Table 3). The state of the state o

158

150

134

Phylum DMB 150 mg **DMB** 300 mg **Placebo Placebo Placebo p-value** Baseline 3 months Baseline 3 months Baseline 3 months Treatment (T) Time (t) T x t *Actinobacteriota* 0.3 $(0.1 - 0.7)$ 0.4 $(0.1 - 0.4)$ 0.2 $(0.03 - 0.7)$ 0.2 $(0.07 - 0.5)$ 0.3 $(0.01 - 0.8)$ 0.1 $(0.03 - 0.6)$ 0.717 0.357 0.468 *Bacillota* 78.1 $(70.6 - 94.1)$ 88.6 (76 - 95.1) 75.7 (49.3 - 86) 74.7 $(67.7 - 80.6)$ 69.1 $(13.1 - 88.1)$ 73.7 (50.3 - 91.1) 0.062 0.224 0.598 *Bacteroidota* 14.6 $(1.4 - 24.5)$ 8.2 $(1.9 - 20.7)$ 8.9 $(3.1 - 41.4)$ 16 $(3 - 26.4)$ 10.2 $(0.008 - 18.1)$ 6.7 $(0.1 - 32.4)$ 0.444 0.674 0.888 *Pseudomonadota* 3.8 $(2.2 - 7.9)$ 2 $(1.2 - 12)$ 7.2 $(4.6 - 24)$ 8.1 $(3.4 - 21.5)$ 16.8 $(2.7 - 86.8)$ 15.9 $(4.2 - 31.4)$ 0.043* 0.253 0.366 *Tenericutes* 0.2 $(0.01 - 0.3)$ 0.06 $(0.01 - 0.2)$ 0.09 $(0.01 - 0.2)$ 0.03 $(0.008 - 0.2)$ 0.1 $(0.006 - 0.4)$ 0.06 $(0.01 - 0.2)$ 0.542 0.092 0.703 *Synergistetes* 0.1 $(0.008 - 0.3)$ 0.08 $(0.01 - 0.2)$ 0.08 $(0.01 - 1.3)$ 0.2 $(0.02 - 0.5)$ 0.2 $(0.05 - 0.2)$ 0.1 $(0.01 - 0.2)$ 0.282 0.397 0.876 *Verrucomicrobiota* 0.1 $(0.006 - 0.9)$ 0.1 $(0.01 - 1.5)$ 0.03 $(0.007 - 1.3)$ 0.05 $(0.01 - 0.2)$ 0.08 $(0.07 - 1.2)$ 0.04 $(0.01 - 2.4)$ 0.616 0.466 0.388 Shannon 3.3 $(2.5 - 3.6)$ 3.3 $(3.1 - 3.8)$ 3.3 $(2.3 - 3.7)$ 3.3 $(2.6 - 3.4)$ 3.3 $(1.5 - 3.3)$ 3.0 $(2.1 - 3.8)$ 0.150 0.879 0.745 Simpson 0.9 $(0.8 - 0.9)$ 0.9 $(0.9 - 1.0)$ 0.9 $(0.8 - 0.9)$ 0.9 $(0.9 - 0.9)$ 0.9 $(0.5 - 0.9)$ 0.9 $(0.8 - 1.0)$ 0.135 0.825 0.579 Chao1 435.2 (308.3 - 548.2) 388.7 (315.0 - 540.0) 404.7 $(255.1 - 684.8)$ 422.6 (261.0 - 491.2) 394.7 (264.3 - 514.2) 415.6 $(272.1 - 547.0)$ 0.367 0.139 0.202

Table 1. Relative abundances of intestinal bacteria at the phylum level in malnourished patients with cancer and dys- 159 geusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months. 160

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates 162 significant differences (p<0.05). 163

164

161

165 166

167

- 168
- 169 170
-
- 171
- 172
- 173
- 174
	- 175
	- 176

- 178
- 179
- 180
- 181
- 182 183

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.20.24312287;](https://doi.org/10.1101/2024.08.20.24312287) this version posted August 22, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-ND 4.0 International license.

Table 2. Relative abundances of intestinal bacteria at the genus level in malnourished patients with cancer and dysgeu- 184 sia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months.

It is made available under a CC-BY-ND 4.0 International license.

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates 187 significant differences (p<0.05). 188

Table 3. Relative abundances of intestinal bacteria at the species level in malnourished patients with cancer and dys- 190 geusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months. 191

189

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates 193 significant differences (p<0.05). 194

2.4. Short-chain fatty acids 196

In all the study groups, acetic acid was the most abundant short-chain fatty acid. For 197 acetic acid there were significant differences between times and the interaction of treat- 198 ment and time. As a result of treatment with the standard dose of DMB, the acetic acid 199 level increased significantly, whereas the level decreased in patients receiving the placebo 200 treatment (Table 4). 201

Table 4. Plasma short-chain fatty acids in malnourished patients with cancer and dysgeusia who received standard- 203 dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months. 204

Short-chain fatty	DMB 150 mg		DMB 300 mg		Placebo		p-value		
acids	Baseline	3 months	Baseline	3 months	Baseline	3 months	Treatment (T)	Time (t)	$T \times t$
Acetic acid	12.8 ± 6.4	$26.7 \pm 6.7^*$	36.6 ± 7.0	31.7 ± 7.3	25.0 ± 7.8	$15.0 \pm 8.2^*$	0.082	$0.032*$	$0.027*$
$(\mu mol/L)$									
Propionic acid	0.8 ± 0.6	2.2 ± 0.9	1.5 ± 0.6	0.6 ± 1.0	1.9 ± 0.7	2.6 ± 1.1	0.357	0.420	0.559
$(\mu \text{mol/L})$									
Isobutyric acid	0.3 ± 0.1	0.4 ± 0.1	0.3 ± 0.1	0.3 ± 0.1	0.4 ± 0.1	0.4 ± 0.1	0.993	0.893	0.955
$(\mu mol/L)$									
Butyric acid	0.9 ± 0.3	1.3 ± 0.3	0.9 ± 0.3	0.8 ± 0.4	1.1 ± 0.3	1.3 ± 0.4	0.698	0.414	0.591
$(\mu mol/L)$									
Isovaleric acid	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1	0.4 ± 0.1	0.865	0.991	0.603
$(\mu \text{mol/L})$									
Valeric acid									
$(\mu \text{mol/L})$	1.0 ± 0.8	2.2 ± 0.9	1.0 ± 1.5	0.7 ± 1.0	1.0 ± 1.9	2.7 ± 1.1	0.573	0.559	0.878

The values are presented as the means and standard deviations. Based on the median test across time points within 206 groups, *indicates significant differences (p<0.05). 207

208

209

210

195

202

It is made available under a CC-BY-ND 4.0 International license.

2.5. Rivera-Pinto for microbiota balance 211

To ascertain the microbiome balance at the conclusion of the trial, the Rivera-Pinto 212 method was employed [46]. The analysis revealed that *Pseudomonadota*, was most associ- 213 ated with the placebo group when the standard-dose DMB group (150 mg) was compared 214 with the placebo group (Figure 1A). In the standard-dose DMB group, lower balance 215 scores were associated with lower relative abundances of *Roseburia, Phocaeicola, Escherichia* 216 and *Streptococcus* than *Pseudomonadota* (Figure 1A). With respect to the high-dose DMB 217 group versus the placebo group, *Escherichia* was the most strongly associated with the 218 placebo group (Figure 1B). Thus, the higher the dose of DMB was, the lower the balance 219 scores associated with lower relative abundances of *Actinobacteriota* than of *Escherichia* 220 (Figure 1B). 221

ROC curve \mathbf{A} **DENOMINATOR NUMERATOR** 100 Roseburia Pseudomonadota Ĕ 0.50 Phocaeicola 0.25 AUC-RO 0.00 Escherichia 0.00 0.25 0.50 0.75 1.00 Streptococcus **FPR** DMB 150 mg Placebo 240 ROC curve \overline{a} **DENOMINATOR NUMERATOR** \overline{v} Actinobacteriota Escherichia 0.000025050075100 EPP 28 $\frac{2}{3}$ DMB 300 mg Placebo

222

باب

Figure 1. Group balances are presented in an overview. The top of the plot indicates that groups of taxa constitute the 256 global balance. Box plots illustrating the distribution of balance scores for the DMB150 mg (standard dose) and placebo 257 groups (A) and the DMB 300 mg (high dose) and placebo groups (B). On the right, the ROC curve with its AUC value 258 and the density curve are displayed. 259

> *2.6. Analysis of the relationships among the intestinal microbiota, nutritional status, electrical* 261 *taste perception inflammatory cytokines, , an plasma short-chain fatty acids.* 262

> In the group of patients with cancer and dysgeusia who received the standard dose 263 of DMB, *Mediterraneibacter* had a negative correlation with saturated fatty acid percentage 264 of energy in the diet. TNF-α levels were positively correlated with *Lachnoclostridium* and 265

It is made available under a CC-BY-ND 4.0 International license.

Mediterraneibacter. The presence of the *Prevotella* genus was positively correlated with the 266 electrogustometry values on the right side of the tongue and the proteolysis inducing fac- 267 tor (Figure 2A). 268

Several correlations were observed in the group that received high doses of DMB 269 (Figure 2B). As a percentage of energy, *Blautia* and *Mediterraneibacter* were positively as- 270 sociated with lipids in the diet, whereas *Faecalibacterium* was negatively associated. *Medi-* 271 *terraneibacter* was positively correlated with dietary monounsaturated fatty acids. There 272 was a positive correlation between dietary polyunsaturated fatty acids (PUFAs) and *Lach-* 273 *noclostridium* and *Roseburia*. Dietary energy intake (%) was positively correlated with *An-* 274 *aerobutyricum*. There was a negative correlation between the relative abundance of *Pho-* 275 *caeicola* and electrogustometry (both, right and left sides of the tongue), and TNF-α levels. 276 Proteolysis inducing factor was positively correlated with the *Prevotella* genus. There was 277 a positive correlation between *Phocaeicola* and plasma acetic acid concentration, whereas 278 a negative correlation was detected between *Pseudomonadota* and TNF-α levels (Figure 279 $2B$). 280

A positive association between *Phocaeicola* and energy intake was detected in the pla- 281 cebo group. Dietary saturated fatty acids (%) were negatively associated with *Lachnospira*. 282 Dietary monounsaturated fatty acids were positively correlated with *Anaerobutyricum* and 283 *Blautia*. Dietary PUFAs were positively correlated with *Mediterraneibacter* and *Roseburia* 284 (Figure 2C). 285

It is made available under a CC-BY-ND 4.0 International license.

Figure 2. Correlations between the intestinal microbiota, nutritional status, electrical taste perception and inflamma-
340 tory cytokines. A. DMB 150 mg (standard dose), B. DMB 300 mg (high dose), and C. placebo. 341

It is made available under a CC-BY-ND 4.0 International license.

3. Discussion 344

The present study revealed that regular DMB consumption together with nutritional 345 treatment and individualized dietary advice changed the composition of the gut microbi- 346 ota. We found that the differences between the genera *Phocaeicola* and *Escherichia* were 347 dependent on the treatment, but only the *Solibaculum* genus presented an increased rela- 348 tive abundance in the standard-dose DMB group following 3 months. After 3 months, 349 *Bacteroides* sp. PHL 2737 showed greater relative abundance in both DMB groups, whereas 350 *Vescimonas coprocola* was more abundant in both treatment groups. According to the elec- 351 trogustometry results on the right side of the tongue of patients with cancer and dysgeusia 352 receiving the standard dose of DMB, the presence of *Prevotella* genus was positively cor- 353 related with the electrogustometry values and proteolysis-inducing factor plasma levels. 354 The TNF-α levels were positively correlated with *Lachnoclostridium* and *Mediterraneibacter*. 355 The abundance of *Mediterraneibacter* was negatively correlated with dietary saturated fatty 356 acids expressed as percentage of the dietary energy. In the group that received high doses 357 of DMB, several correlations were observed. A negative correlation was found between 358 the relative abundance of *Phocaeicola* and electrogustometry (both right and left sides of 359 the tongue) as well as $TNF-\alpha$ levels. The proteolysis inducing factor was positively corre- 360 lated with the *Prevotella* genus. *Anaerobutyricum* was positively correlated with the energy 361 intake. *Blautia* and *Mediterraneibacter* were positively associated with lipids in the diet, 362 whereas *Faecalibacterium* was negatively associated. The correlation between *Mediterranei-* 363 *bacter* and monounsaturated fatty acids was positive. *Lachnoclostridium* and *Roseburia* were 364 positively correlated with dietary PUFAs. Also, our results revealed that *Phocaeicola* was 365 positively correlated with the plasma acetic acid concentration, whereas *Pseudomonadota* 366 was negatively correlated with the TNF-α levels. **367** and 367

According to Hes et al. (2024), the gut microbiome of patients with severe mucositis 368 differ from that of patients with grades 1-2 mucositis, with an increase in the abundances 369 of *Mediterraneibacter (Ruminococcus gnavus*) and *Clostridiaceae*, including *Hungatella hathe-* 370 *wayi* [47]. As shown here, the habitual consumption of a standard dose of DMB was posi-
 tively associated with TNF-α levels and *Lachnoclostridium,* and *Mediterraneibacter* abun- 372 dances, whereas a high dose of DMB was negatively associated with $TNF-\alpha$ levels and the 373 relative abundance of *Phocaeicola*. Microbes, as well as gut bacteria-derived metabolites, 374 pathogen-associated molecular patterns, and antigens, can move from the gastrointestinal 375 tract to other closely related tissues and impact cancer progression [48]. 376

The *Bacteroides* and *Phocaeicola* species play crucial roles in the human colon. By de- 377 grading complex heteropolysaccharides into short-chain fatty acids, those organisms con- 378 tribute to the body's use of these compounds [49]. Our findings indicate that the consump- 379 tion of DMB at high doses is positively correlated with the abundance of the genus *Pho-* 380 *caeicola* and acetic acid concentrations. In addition, following DMB administration at a 381 high dose, a positive correlation was found between PUFAs, *Lachnoclostridium*, and *Rose-* 382 *buria*. PUFAs have antitumor activity. In particular, it has been proposed that PUFAs, spe- 383 cifically eicosapentaenoic acid and docosahexaenoic acid, possess anticolorectal cancer ac- 384 tivity [50]. A recent study investigated the impact of PUFA supplementation on the fecal 385 microbiome in middle-aged, healthy volunteers, showing that PUFA supplementation 386 leads to a reversible increase in bacteria that produce short-chain fatty acids [51]. Moreo- 387 ver, a reversible increase in the abundance of several bacterial genera, including *Bifidobac-* 388 *terium*, *Roseburia* and *Lactobacillus*, was observed in patients who received one or both 389 PUFA treatments. Consequently, a high dose of DMB may enhance the presence of micro- 390 organisms that increase SCFA availability and contribute to PUFA consumption. 391

Numerous diseases in humans have been associated with changes in the gut micro- 392 biota composition, with fluctuations in the prevalence of particular bacterial groups. In 393 this regard, *Faecalibacterium* is one of the most notable genera. The relative abundance of 394 this bacteria was estimated to be between 11 and 20%. A recent study revealed a negative $\frac{395}{2}$ correlation between the abundance of *Faecalibacterium* and increased intraindividual var- 396 iability in microbiota composition, indicating that it as a keystone taxon [52,53]. 397

It is made available under a CC-BY-ND 4.0 International license.

Certain species of *Faecalibacterium* have been observed to undergo alterations in a 398 number of diseases and disorders. In fact, multiple studies have demonstrated that a high 399 baseline level of *Faecalibacterium*, along with that of other *Bacillota*, is positively correlated 400 with responses to related treatments for various cancers, including melanoma [54-58], 401 hepatocellular carcinoma [59] and non-small cell lung cancer [60]. We observed a ten- 402 dency to decrease concentration of *Faecalibacterium prausnitzii* in DMB groups. 403

We showed that standard dose of DMB administration resulted in a significant in- 404 crease in the relative abundance of *Solibaculum* genus, whereas placebo resulted in a re- 405 duction of this genus. We identified four species of microbes that are dominant within 406 the gastrointestinal tract of patients with cancer: *Faecalibacterium prausnitzii*, *Anaerobutyri-* 407 *cum hallii*, *Vescimonas* species*, V. coprocola* and *V. fastidiosa*. However, we identified signif- 408 icant differences in the interaction effect between treatment and time for *Bacteroides* sp. 409 PHL 2737 and *Vescimonas coprocola*. A significant decrease in *Bacteroides* sp. PHL 2737 lev- 410 els was observed between the baseline and the three-month period in both the DMB 411 groups. Additionally, *Vescimonas coprocola* levels decreased significantly in the placebo 412 group. Environmental alterations caused by dysbiosis can result in a gradual decline of 413 functional redundancy, either as a consequence of disease or its treatment. A recent study 414 demonstrated that colorectal cancer is influenced by the co-occurrence of species, includ- 415 ing *Vescimonas coprocola* and *Vescimonas fastidiosa*, although they did not significantly differ 416 in abundance [61]. Metagenomic studies based on colorectal cancer datasets have reported 417 an association between specific microbial species and this type of cancer [62-70]. For ex- 418 ample, multiple studies have demonstrated the main role of particular species in the de- 419 velopment of colorectal cancer [71], such as *Streptococcus gallolyticus* [72], *Bacteroides fragilis* 420 [73,74] and *Fusobacterium nucleatum* [75-77]. Moreover, it has been proposed that *Bac-* 421 *teroides fragilis* [73,74] and *Fusobacterium nucleatum* [75-77] are key factors in the tumor- 422 igenesis process and then they may be replaced by "passenger" species that are favored 423 by the cancer microenvironment [78]. 424

The intake of DMB together with nutritional treatment and individualized dietary 425 advice results in positive changes in the intestinal microbiome of cancer patients and pa- 426 tients with dysgeusia, which are correlated with taste perception in the DMB high dose 427 group. By utilizing these strategies, patients with cancer are able to maintain their nutri- 428 tional intake and enjoy their meals despite changes in taste perception and aftertaste [79]. 429 It is, however, important for patients to discuss their dietary preferences and modifica- 430 tions with healthcare professionals in order to ensure that they receive adequate nutrition 431 while undergoing cancer treatment [79]. The ability to manipulate gut microbiome com-
432 position to improve cancer therapy outcomes is a significant new area of research [80,81]. 433 Intestinal microbiome composition is susceptible to changes due to diet and the environ- 434 ment, so educating patients on food consumption during cancer treatment and avoiding 435 carcinogens may improve outcomes [80,81]. 436

Cancer patients receiving a standard dose or a higher dose of DMB experienced dif- 437 ferent changes in their gut microbiota from those receiving a placebo. The difference could 438 be attributed to the sweet taste experienced following the ingestion of orodispersible DMB 439 tablets before each main meal, compared to the placebo group, which may lead to a better 440 dietary intake. 441

4. Materials and Methods 442

4.1. Statement of ethical principles 443

This project was approved by University Hospital La Paz's (HULP Code 6164) Scien- 444 tific Research and Ethics Committee in June 2022. According to the Declaration of Hel- 445 sinki's Ethical Standards, this study adheres to recommendations for physicians conduct- 446 ing biomedical research on humans. The ICH Harmonized Tripartite Guidelines should 447 be familiarized and followed by all researchers in order to maintain good clinical prac- 448 tices. 449

The research team informed the patients (verbally and in writing) of the study char- 450 acteristics and the responsibilities of participation in the trial before they signed the 451

It is made available under a CC-BY-ND 4.0 International license.

informed consent form. Patients were informed during the study that they could with- 452 draw from the study at any time by notifying their doctor without giving a reason. The 453 processing of personal information is subject to several legal requirements, including 454 Spanish Organic Law 3/2018 of 5 December and the General Data Protection Regulation 455 of the European Union (EU) 2016/679 of 27 April 2016. 456

4.2. *Participants and experimental design* 458

Detailed information of CLINMIR study is published elsewhere [43,45]. Briefly, the 459 CLINMIR study is a pilot randomized, parallel, triple-blind, and placebo-controlled clin- 460 ical trial. Using the number NCT05486260, the present protocol was registered at 461 http://clinicaltrials.gov, accessed on 14 March 2024. An oncology service and clinical nu- 462 trition unit at HULP in Madrid recruited 31 malnourished cancer patients with taste dis- 463 orders. 464

Three treatment arms were randomly assigned to malnourished patients with cancer 465 and taste disorders who were receiving active treatment. A miraculin-based food supple- 466 ment was administered to patients five minutes prior to each meal (breakfast, lunch, and 467 dinner) during a three-month study. The tablets contained either DMB at one of its two 468 dosages or a placebo [43,45]. 469

Each intervention group consisted of ten patients who were randomly assigned to 470 receive one of two DMB dosages or a placebo. In the first arm of the study, 150 mg of DMB 471 equivalent to 2.8 mg of miraculin is combined with 150 mg of freeze-dried strawberries; 472 in the second arm, 300 mg of DMB is utilized equivalent to 5.5 mg of miraculin; and in the 473 third arm, 300 mg of freeze-dried strawberries are used as a placebo. Each of the three 474 treatments was isocaloric (Table S1). The subjects received as many tablets as necessary 475 during scheduled visits to the HULP in order to complete the three-month intervention 476 period [43,45]. 477

4.3. *Sequencing of biological samples* 479

To prepare for the analyses, sterile plastic containers were used to collect fecal sam- 480 ples at baseline and 3 months after intervention. Blood samples were collected by trained 481 personnel at the HULP Extraction Unit in the morning (approximately at 8:00 am) during 482 blood tests before chemotherapy to avoid unnecessary punctures and hospitalizations. 483 The blood samples were collected in vacuum tubes, labeled, transported, and centrifuged 484 at $1500 \times g$ for 10 minutes. We prepared and labeled aliquots of blood samples according 485 to a numerical code and stored them at -80 °C. 486

4.3.1. Extraction of DNA 488

QIAamp Fast DNA Stool Mini kit (ref. ID: 51604, Qiagen Inc., Hilden, Germany) was 489 used to extract DNA from the stool samples. The purity and integrity of DNA were deter- 490 mined using spectrophotometry (NanoDrop, Thermo Fisher Scientific, Massachusetts, 491 USA). 492

4.3.2. 16S rRNA gene sequencing and taxonomic assignment 494

A detailed description of 16S sequencing via Oxford Nanopore Technologies can be 495 found elsewhere [44]. Briefly, the 16S rRNA gene was PCR-amplified using redesigned 496 16S primers (27F and 1492R) with 5' tags that facilitate ligase-free attachment. By vortexing 497 30 µl of AMPure XP beads (Beckman Coulter, ThermoScientific, Spain), and mixing by 498 pipetting, PCR products from each sample were cleaned. 499

In order to achieve a concentration of 50-100 fmoles, all barcoded libraries were com- 500 bined in the appropriate ratios. The final library was loaded into the SpotON Flow Cell 501 Mk R9 Version (ref. FLO-MIN106D, Oxford Nanopore Technologies, Oxford, United 502 Kingdom) using the Minion M1kc and M1kb sequencers (Oxford Nanopore Technologies, 503 Oxford, United Kingdom). 504

After the raw data had been generated, searches were performed via Guppy ver- 505 sion 6.5.7 (Oxford Nanopore Technologies, Oxford, United Kingdom), and sequences 506

457

478

It is made available under a CC-BY-ND 4.0 International license.

were identified using Kraken2 (refseq Archaea, bacteria, viral, plasmid, human, Uni- 507 Vec_Core, protozoa, fungi & plant database) and further analyzed using QIIME2 [82]. As- 508 signing taxonomy to ASVs was performed using the classify sklearn naïve Bayes taxon- 509 omy classifier (via q2-feature-classifier) [83] using SILVA 16S V3-V4 v132_99 [84] with a 510 similarity threshold of 99%. The diversity of the samples was examined using the vegan 511 library [85]. In this study, Shannon, Simpson and Chao1 indices were examined. 512

4.4. *Plasma cytokines* 514

Plasma tumor necrosis factor-alpha (TNF- α), and human proteolysis-inducing factor 515 (PIF) were analyzed as previously described [86]. 516

4.5. *Dietary pattern assessment* 518

For three days, including one holiday, daily food records were kept. Patients were 519 advised to record household measurements (spoonfuls, cups, etc.) or household weights 520 in the absence of weight records. A nutritionist reviewed all records in the presence of the 521 patient to ensure that the information collected was accurate and complete. DIAL software 522 (Alce Ingeniera, Madrid, Spain) was used to convert the energy and nutrients contained 523 in foods, drinks, dietary supplements, and preparations. Finally, the results were com- 524 pared with the recommended intakes for the Spanish population [43,45]. 525

4.6. *Short-chain fatty acids determination by gas chromatography/mass spectrometry* 527

One hundred µl of plasma were individually placed in 1.5 ml tubes. Afterward, 10 528 μ L of acidified water (15 % phosphoric acid v/v), and 10 μ l of internal standards (sodium 529 acetate ¹³C2 at 300 µM, butyric-1,2⁻¹³C2 at 60 µM and isobutyric acid d6, valeric acid d9, 530 isovaleric acid d9 and propionic d6 acid at 30 μ M) are added and vigorously mixed up. 531 Next, a liquid-liquid extraction was performed with 150 µl of MTBE. The extraction was 532 assisted by vortexing for 10 minutes. At this point, tubes were centrifuged at 15000 rpm 533 for 10 minutes at 4 °C. One hundred µl were transferred into a vial with an insert. The 534 vials were centrifuged at 1000 rpm for 30s at 4° C and 1 µl was injected into gas chroma- 535 tography/mass spectrometry. Briefly, short-chain fatty acids were separated on a DB- 536 FFAP chromatographic column (30 m x 0.25 mm x 0.25 µm). The oven temperature was 537 programmed as follows: (i) initial temperature 40 $^{\circ}$ C, (ii) linearly increased at 12 $^{\circ}$ C/min 538 until 130 °C (0 min), (iii) then linearly raised at 30 °C/min to 200 °C (0 min) and (iv) in the 539 final step the temperature was ramped at 100 °C/min to 250 °C (4.5 min). The column flow 540 was set at 1.5 ml/min with Helium as carrier gas. The injector was set at 250 $^{\circ}$ C and the 541 extract was injected in a split-less mode. Using electronic impact (70 eV) for ionization, 542 the mass analyzer was operated for multi reaction monitoring. 543

4.7. *Statistical analysis* 545

To examine the effects of time, treatment, and their interaction (time x treatment), a 546 linear mixed model was used to examine the differences between placebo, 150 mg of DMB, 547 and 300 mg DMB. Using the R program, a linear mixed model was developed using the 548 lme4 package [87]. A median test revealed significant differences across time points 549 within groups. 550

We also examined the relationships between intestinal microbiome variables, inflam- 551 matory parameters, dietary variables, short-chain fatty acids, and electrical taste percep- 552 tion outcomes via Pearson's correlations; for that purpose we used the R Studio's corrplot 553 function [88] correcting multiple testing using the FDR procedure [89]. Only significant 554 and corrected associations are shown in the graphs. The red and blue lines in the graphs 555 indicate correlation values, with negative correlations highlighted in red (−1) and positive 556 correlations highlighted in blue (+1). 557

Rivera-Pinto analysis can identify microbial signatures, i.e., groups of microbes ca- 558 pable of predicting particular phenotypes of interest. This microbial signature may be 559 used to diagnose, prognosticate, or predict therapeutic response on the basis of the unique 560 microbiota of an individual. Identifying microbial signatures requires modeling the 561

544

513

517

It is made available under a CC-BY-ND 4.0 International license.

response variable and selecting the taxa that are the most accurate at classification or pre- 562 diction. To select a sparse model that adequately explains the response variable, we eval- 563 uated specific signatures at the phylum and genus levels using the Rivera-Pinto method 564 and the Selbal algorithm. Based on data collected from two groups of taxa, microbial sig- 565 natures were calculated using geometric means. These groups are those with relative 566 abundances or balances that are related to the response variable of interest [46]. 567

5. Conclusions 568

This pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial 569 identified a putative innovative therapeutic option for the management of taste disorders 570 in patients with cancer. This novel strategy was designed with the intent of reducing the 571 adverse effects associated with chemotherapeutic, radiotherapeutic, and immunothera- 572 peutic interventions, which may include alterations in taste, changes in body composition 573 and nutritional status, and alterations in the quality of life [45]. Here, we observed differ- 574 ences between the genera *Phocaeicola* and *Escherichia* depending on the treatment. Only 575 the *Solibaculum* genus increased in relative abundance in the DMB group after 3 months. 576 With respect to species, *Bacteroides* sp. PHL 2737 had a lower relative abundance in both 577 DMB groups, and *Vescimonas coprocola* exhibited a greater abundance in both treatments 578 after 3 months. Moreover, a standard dose of DMB was positively associated with $TNF-\alpha$ 579 levels and *Lachnoclostridium* and *Mediterraneibacter* abundances, whereas a high dose of 580 DMB was negatively associated with TNF-α levels and the relative abundance of *Pho-* 581 *caeicola*. After high- dose DMB administration, a positive correlation was found between 582 PUFAs, *Lachnoclostridium*, and *Roseburia*. Additionally *Phocaeicola* was positively corre- 583 lated with acetic acid levels. Accordingly, DMB intake and nutritional treatment posi- 584 tively modify the intestinal microbiome in patients with cancer and dysgeusia, which 585 might lead to a greater immunological response and better dietary intake. 586

Supplementary Materials: The following supporting information can be downloaded at: 587 www.mdpi.com/xxx/s1, Table S1: Nutritional composition of the food supplement enriched in mi- 588 raculin (DMB) and placebo. 589

Author Contributions: Conceptualization, B.L.-P., A.G. and S.P.-M.; methodology, B.L.-P. and J.F.- 590 B.; software, J.D.-P.; validation, F.J.R.-O, A.I.A.-M. and M.B.-H.; formal data analysis, J.D.-P., F.J.R.- 591 O, and M.B.-H.; investigation, B.L.-P and L.A.-C.; resources, S.P.-M.; data curation, L.A.-C; writing- 592 original draft preparation, J.D.-P., F.J.R.-O, M.B.-H. and A.G.; writing-review and editing, J.D.-P., 593 F.J.R.-O, M.B.-H. and A.G.; supervision, S.P.-M and A.G.; project administration, B.L.-P; funding 594 acquisition, S.P.-M. All authors have read and agreed to the published version of the manuscript. 595

Funding: This study is funded by Medicinal Gardens S.L. through the Center for Industrial Tech- 596 nological Development (CDTI), "Cervera" Transfer R&D Projects. Ref. IDI-20210622. (Science and 597 Education Ministry, Spain). 598

Institutional Review Board Statement: The study was conducted under the Declaration of Helsinki, 599 and approved by the Ethics Committee of La Paz University Hospital (protocol code 6164, 23 June 600 2022). 601

Informed Consent Statement: Informed consent was obtained from all subjects involved in the 602 study. 603

Data Availability Statement: A reasonable request should be made to the corresponding author for 604 access to the datasets used and/or analyzed in the current study. 605

Acknowledgments: J.P.-D. is part of the "UGR Plan Propio de Investigación 2016" and the "Excel- 606 lence actions: Unit of Excellence in Exercise and Health (UCEES), University of Granada". F.J.R.-O. 607 is supported by a grant from the Spanish Government's "Agencia Estatal de Investigación-Juan de 608 la Cierva-Incorporación" program (IJC2020-042739-I). We thank (Lucía Tadeo, Helena Torrell, Adría 609 Cereto and Núria Canela) from the Genomics facility of the Centre for Omic Sciences (COS) Joint 610 Unit of the Universitat Rovira i Virgili-Eurecat, for their contributions to the sequencing analysis. 611

Conflicts of Interest: The authors declare that they have no commercial or financial relationships 612 that could be construed as potential conflicts of interest. 613

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.20.24312287;](https://doi.org/10.1101/2024.08.20.24312287) this version posted August 22, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-ND 4.0 International license.

References 614

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.20.24312287;](https://doi.org/10.1101/2024.08.20.24312287) this version posted August 22, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-ND 4.0 International license.

- 39. Gomez de Cedron, M.; Wagner, S.; Reguero, M.; Menendez-Rey, A.; de Molina, A.R. Miracle Berry as a Potential Supplement 704 in the Control of Metabolic Risk Factors in Cancer. *Antioxidants (Basel)* **2020**, *9*, doi:10.3390/antiox9121282. 705
- 40. Soares, H.; Cusnir, M.; Schwartz, M.; Pizzolato, J.; Lutzky, J.; Campbell, R.; Beaumont, J.; Eton, D.; Stonick, S.; Lilenbaum, R. 706 Treatment of taste alterations in chemotherapy patients using the "miracle fruit": Preliminary analysis of a pilot study. 707 *Journal of Clinical Oncology* **2010**, *28*, e19523-e19523. 708
- 41. Osabor, V.; Etiuma, R.; Ntinya, M. Chemical profile of leaves and roots of miracle fruit (Synsepalum dulcificum). *American* 709 *Chemical Science Journal* **2016**, *12*, 1-8. 710
- 42. He, Z.; Tan, J.S.; Abbasiliasi, S.; Lai, O.M.; Tam, Y.J.; Ariff, A.B. Phytochemicals, nutritionals and antioxidant properties of 711 miracle fruit Synsepalum dulcificum. *Industrial Crops and Products* **2016**, *86*, 87-94. 712
- 43. López-Plaza, B.; Gil, Á.; Menéndez-Rey, A.; Bensadon-Naeder, L.; Hummel, T.; Feliú-Batlle, J.; Palma-Milla, S. Effect of 713 Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished 714 Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial-CLINMIR Pilot Protocol. *Nutrients* **2023**, *15*, 715 doi:10.3390/nu15214639. 716
- 44. Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; López-Plaza, B.; Brandimonte-Hernández, M.; Álvarez-Mercado, A.I.; Arcos-Castellanos, L.; 717 Feliú-Batlle, J.; Hummel, T.; Palma-Milla, S.; Gil, A. Effect of a novel food rich in miraculin on the oral microbiome of 718 malnourished oncologic patients with dysgeusia. *medRxiv* **2024**, 10.1101/2024.07.12.24310343, 2024.2007.2012.24310343, 719 doi:10.1101/2024.07.12.24310343. 720
- 45. López-Plaza, B.; Álvarez-Mercado, A.I.; Arcos-Castellanos, L.; Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Brandimonte-Hernández, M.; 721 Feliú-Batlle, J.; Hummel, T.; Gil, Á.; Palma-Milla, S. Efficacy and Safety of Habitual Consumption of a Food Supplement 722 Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study. *Nutrients* **2024**, *16*, 1905, 723 doi:10.3390/nu16121905. 724
- 46. Rivera-Pinto, J.; Egozcue, J.J.; Pawlowsky-Glahn, V.; Paredes, R.; Noguera-Julian, M.; Calle, M.L. Balances: a New 725 Perspective for Microbiome Analysis. *mSystems* **2018**, *3*, doi:10.1128/mSystems.00053-18. 726
- 47. Hes, C.; Desilets, A.; Tonneau, M.; El Ouarzadi, O.; De Figueiredo Sousa, M.; Bahig, H.; Filion, E.; Nguyen-Tan, P.F.; 727 Christopoulos, A.; Benlaifaoui, M., et al. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation 728 therapy in patients with head and neck squamous cell carcinoma. *Oral Oncol* **2024**, *148*, 106623, 729 doi:10.1016/j.oraloncology.2023.106623. 730
- 48. Ma, C.; Han, M.; Heinrich, B.; Fu, Q.; Zhang, Q.; Sandhu, M.; Agdashian, D.; Terabe, M.; Berzofsky, J.A.; Fako, V. Gut 731 microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. *Science* **2018**, *360*, eaan5931. 732
- 49. Luck, R.; Deppenmeier, U. Genetic tools for the redirection of the central carbon flow towards the production of lactate in 733 the human gut bacterium Phocaeicola (Bacteroides) vulgatus. *Appl Microbiol Biotechnol* **2022**, *106*, 1211-1225, 734 doi:10.1007/s00253-022-11777-6. 735
- 50. Nabavi, S.F.; Bilotto, S.; Russo, G.L.; Orhan, I.E.; Habtemariam, S.; Daglia, M.; Devi, K.P.; Loizzo, M.R.; Tundis, R.; Nabavi, 736 S.M. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. *Cancer and Metastasis Reviews* **2015**, 737 *34*, 359-380. 738
- 51. Watson, H.; Mitra, S.; Croden, F.C.; Taylor, M.; Wood, H.M.; Perry, S.L.; Spencer, J.A.; Quirke, P.; Toogood, G.J.; Lawton, 739 C.L., et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal 740 microbiota. *Gut* **2018**, *67*, 1974-1983, doi:10.1136/gutjnl-2017-314968. 741
- 52. Olsson, L.M.; Boulund, F.; Nilsson, S.; Khan, M.T.; Gummesson, A.; Fagerberg, L.; Engstrand, L.; Perkins, R.; Uhlen, M.; 742 Bergström, G. Dynamics of the normal gut microbiota: a longitudinal one-year population study in Sweden. *Cell host &* 743 *microbe* **2022**, *30*, 726-739. e723. 744

- 54. Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M. 747 Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. 748 *Annals of Oncology* **2017**, *28*, 1368-1379. 749
- 55. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.; Vicente, D.; Hoffman, 750 K.; Wei, S.C. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. *Science* **2018**, *359*, 751 97-103. 752
- 56. Coutzac, C.; Jouniaux, J.-M.; Paci, A.; Schmidt, J.; Mallardo, D.; Seck, A.; Asvatourian, V.; Cassard, L.; Saulnier, P.; Lacroix, 753 L. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. *Nature communications* 754 **2020**, *11*, 2168. 755
- 57. Limeta, A.; Ji, B.; Levin, M.; Gatto, F.; Nielsen, J. Meta-analysis of the gut microbiota in predicting response to cancer 756 immunotherapy in metastatic melanoma. *JCI insight* **2020**, *5*. 757
- 58. Spencer, C.N.; McQuade, J.L.; Gopalakrishnan, V.; McCulloch, J.A.; Vetizou, M.; Cogdill, A.P.; Khan, M.A.W.; Zhang, X.; 758 White, M.G.; Peterson, C.B. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy 759 response. *Science* **2021**, *374*, 1632-1640. 760
- 59. Lili, L.; Ye, J. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune 761 checkpoint inhibitors: A Chinese population-based study. *Medicine* **2020**, *99*, e21788. 762
- 60. Newsome, R.C.; Gharaibeh, R.Z.; Pierce, C.M.; da Silva, W.V.; Paul, S.; Hogue, S.R.; Yu, Q.; Antonia, S.; Conejo-Garcia, J.R.; 763 Robinson, L.A. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade 764 in a United States cohort. *Genome Medicine* **2022**, *14*, 35. 765
- 61. Riveros Escalona, M.A.; Poloni, J.F.; Krause, M.J.; Dorn, M. Meta-analyses of host metagenomes from colorectal cancer 766 patients reveal strong relationship between colorectal cancer-associated species. *Mol Omics* **2023**, *19*, 429-444, 767 doi:10.1039/d3mo00021d. 768
- 62. Zuo, W.; Michail, S.; Sun, F. Metagenomic analyses of multiple gut datasets revealed the association of phage signatures in 769 colorectal cancer. *Frontiers in cellular and infection microbiology* **2022**, *12*, 918010. 770
- 63. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.-J.; Campbell, B.J.; Abujamel, T.; Dogan, 771 B.; Rogers, A.B. Intestinal inflammation targets cancer-inducing activity of the microbiota. *science* **2012**, *338*, 120-123. 772
- 64. Heshiki, Y.; Vazquez-Uribe, R.; Li, J.; Ni, Y.; Quainoo, S.; Imamovic, L.; Li, J.; Sørensen, M.; Chow, B.K.; Weiss, G.J. 773 Predictable modulation of cancer treatment outcomes by the gut microbiota. *Microbiome* **2020**, *8*, 1-14. 774
- 65. Thomas, A.M.; Manghi, P.; Asnicar, F.; Pasolli, E.; Armanini, F.; Zolfo, M.; Beghini, F.; Manara, S.; Karcher, N.; Pozzi, C. 775 Author Correction: Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic 776 signatures and a link with choline degradation. *Nature medicine* **2019**, *25*, 1948-1948. 777
- 66. Ulger Toprak, N.; Yagci, A.; Gulluoglu, B.; Akin, M.; Demirkalem, P.; Celenk, T.; Soyletir, G. A possible role of Bacteroides 778 fragilis enterotoxin in the aetiology of colorectal cancer. *Clinical microbiology and infection* **2006**, *12*, 782-786. 779
- 67. Wirbel, J.; Pyl, P.T.; Kartal, E.; Zych, K.; Kashani, A.; Milanese, A.; Fleck, J.S.; Voigt, A.Y.; Palleja, A.; Ponnudurai, R. Meta- 780 analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nature medicine* **2019**, 781 *25*, 679-689. 782
- 68. Zeller, G.; Tap, J.; Voigt, A.Y.; Sunagawa, S.; Kultima, J.R.; Costea, P.I.; Amiot, A.; Böhm, J.; Brunetti, F.; Habermann, N. 783 Potential of fecal microbiota for early‐stage detection of colorectal cancer. *Molecular systems biology* **2014**, *10*, 766. 784
- 69. Briscoe, L.; Balliu, B.; Sankararaman, S.; Halperin, E.; Garud, N.R. Evaluating supervised and unsupervised background 785 noise correction in human gut microbiome data. *PLOS Computational Biology* **2022**, *18*, e1009838. 786

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.20.24312287;](https://doi.org/10.1101/2024.08.20.24312287) this version posted August 22, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Disorders: The CLINMIR Pilot Study. *medRxiv* **2024**, 10.1101/2024.06.23.24309349, 2024.2006.2023.24309349, 830 doi:10.1101/2024.06.23.24309349. 831

- 87. Wang, T.; Graves, B.; Rosseel, Y.; Merkle, E.C. Computation and application of generalized linear mixed model derivatives 832 using lme4. *Psychometrika* **2022**, *87*, 1173-1193, doi:10.1007/s11336-022-09840-2. 833
- 88. Wei, T.S., V; Levy, M; Xie, Y; Jin Y; Zemla, J; Freidank, M; Cai, J; Protivinsky, T. Package 'corrplot'. 834 *<https://github.com/taiyun/corrplot>* **2022**. 835
- 89. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. 836 *Journal of the Royal Statistical Society: Series B (Methodological)* **1995**, *57*, 289-300, doi[:https://doi.org/10.1111/j.2517-](https://doi.org/10.1111/j.2517-6161.1995.tb02031.x) 837 [6161.1995.tb02031.x.](https://doi.org/10.1111/j.2517-6161.1995.tb02031.x) 838